Medistim ASA

LSE:0OCD Stock Report

Market Cap: NOK 3.6b

Medistim Management

Management criteria checks 3/4

Medistim's CEO is Kari Krogstad, appointed in Sep 2009, has a tenure of 15.67 years. total yearly compensation is NOK5.40M, comprised of 61.9% salary and 38.1% bonuses, including company stock and options. directly owns 0.26% of the company’s shares, worth NOK9.20M. The average tenure of the management team and the board of directors is 6.1 years and 1.7 years respectively.

Key information

Kari Krogstad

Chief executive officer

NOK 5.4m

Total compensation

CEO salary percentage61.9%
CEO tenure15.7yrs
CEO ownership0.3%
Management average tenure6.1yrs
Board average tenure1.7yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Kari Krogstad's remuneration changed compared to Medistim's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2025n/an/a

NOK 123m

Dec 31 2024NOK 5mNOK 3m

NOK 104m

Sep 30 2024n/an/a

NOK 102m

Jun 30 2024n/an/a

NOK 104m

Mar 31 2024n/an/a

NOK 103m

Dec 31 2023NOK 7mNOK 3m

NOK 104m

Sep 30 2023n/an/a

NOK 117m

Jun 30 2023n/an/a

NOK 116m

Mar 31 2023n/an/a

NOK 116m

Dec 31 2022NOK 9mNOK 3m

NOK 114m

Sep 30 2022n/an/a

NOK 98m

Jun 30 2022n/an/a

NOK 92m

Mar 31 2022n/an/a

NOK 93m

Dec 31 2021NOK 6mNOK 3m

NOK 91m

Sep 30 2021n/an/a

NOK 88m

Jun 30 2021n/an/a

NOK 84m

Mar 31 2021n/an/a

NOK 70m

Dec 31 2020NOK 6mNOK 3m

NOK 69m

Sep 30 2020n/an/a

NOK 71m

Jun 30 2020n/an/a

NOK 74m

Mar 31 2020n/an/a

NOK 75m

Dec 31 2019NOK 4mNOK 3m

NOK 70m

Sep 30 2019n/an/a

NOK 79m

Jun 30 2019n/an/a

NOK 73m

Mar 31 2019n/an/a

NOK 64m

Dec 31 2018NOK 4mNOK 2m

NOK 57m

Compensation vs Market: Kari's total compensation ($USD520.90K) is below average for companies of similar size in the UK market ($USD1.13M).

Compensation vs Earnings: Kari's compensation has been consistent with company performance over the past year.

CEO

Kari Krogstad (60 yo)

15.7yrs

Tenure

NOK 5,395,092

Compensation

Ms. Kari Eian Krogstad serves as Independent Director at Vistin Pharma ASA since June 24, a2020. She has been the Chief Executive Officer of Medistim ASA since September 1, 2009 and serves as its President...

Leadership Team

NamePositionTenureCompensationOwnership
Kari Krogstad
CEO & President15.7yrsNOK 5.40m0.26%
NOK 9.2m
Thomas Jakobsen
Chief Financial Officerno dataNOK 2.26m0.17%
NOK 6.0m
Helge Borslid
Vice President of Operationsno dataNOK 1.70mno data
Hæge Johanne Wetterhus
Vice President of Marketing14.8yrsNOK 1.84m0.0087%
NOK 311.1k
Hakon Grothe
Chief Innovation Officer6.1yrsNOK 1.85m0.043%
NOK 1.5m
Ole Eiksund
Chief Business Development Officer3.1yrsNOK 1.77m0.032%
NOK 1.1m
Roger Morberg
Vice President of Sales - APACno dataNOK 2.08m0.089%
NOK 3.2m
Stephanie Stenhagen
Vice President of Sales EMEAno dataNOK 1.71m0.015%
NOK 544.4k
Mike Karim
Chief Commercial Officerless than a yearno datano data
Ole Robsrud
Managing Director of Medistim Norge ASno dataNOK 1.83m0%
NOK 0

6.1yrs

Average Tenure

60yo

Average Age

Experienced Management: 0OCD's management team is seasoned and experienced (6.1 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Oyvin Broymer
Chairman25.3yrsNOK 520.00k0%
NOK 0
Anna Ahlberg
Independent Director2.1yrsNOK 325.00k0.0022%
NOK 78.1k
Tove Raanes
Independent Director11.3yrsNOK 340.00k0.011%
NOK 389.2k
Peder Strand
Director1.3yrsNOK 305.00kno data
Gry Dahle
Independent Director1.3yrsNOK 290.00kno data
Rune Halvorsen
Directorno datano datano data

1.7yrs

Average Tenure

50.5yo

Average Age

Experienced Board: 0OCD's board of directors are not considered experienced ( 1.7 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/11 11:52
End of Day Share Price 2025/05/09 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Medistim ASA is covered by 4 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Magnus GranerødBeringer Finance AB
Karl NorénDanske Bank
Geir HolomDNB Markets